OIVD/DMD - Center for Devices and Radiological Health 被引量: 1发表: 0年 OPHTHALMIC COMPOSITION COMPRISING ASCOMYCIN This invention relates to topical ophthalmic compositions comprising an ascomycin e.g. for the treatment of inflammatory diseases such as blepharitis. BABIOLE SAUNIER Maggy,BIZEC Jean-...
Latest on EWTX: Exclusive BAC Article: Edgewise Therapeutics; DMD Data 1st Half Of 2024, Three Data Readouts BMD This Year, Late-Stage Program Advancements And Catalysts The Biotech Forum 4.7Bret Jensen Themes: Biotech Latest on EWTX: Edgewise Therapeutics: A New Holding Pen Position IPO Edge...
Capricors cell therapy shows three year benefit in DMD patients (Clinical Trials Arena) Jun-28-24 09:00AM Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy ...
Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself ApartTerry ChrisomalisTue, Jan. 213 Comments Buy Solid Biosciences: Unpacking Its Main Value DriverMyriam AlvarezWed, Apr. 10, 20242 Comments Solid Biosciences: DMD Treatment Advancement With Next-Generation CapsidTerry ChrisomalisTue...
Markets change, but our community always has the latest news, in-depth analysis, and powerful stock ratings. Continue with Google Continue with Apple or Create Free Account By creating an account using any of the options above, you agree to theTerms of Use&Privacy Policy ...
It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular ...
Latest on RNA:Exclusive BAC Article: Avidity Biosciences; 5 Mg/Kg AOC 1044 Cohort Data DMD 2nd Half Of 2024, Q2 2024 FSHD Data, Phase 3 Trial Initiation DM1 And Catalysts Haggerston BioHealth 5.0 Edmund Ingham Themes: Biotech Latest on RNA:Avidity Biosciences: Targeting A First Ever Approval...
(DMD), and obesity, as well as treatment of severe respiratory failure in patients suffering from COVID-19. It also develops BIO201, an orally administered small molecule for the treatment of retinopathies, including dry age-related macular degeneration, and Stargardt disease. Biophytis SA has...
The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in...
If BTMD were to pay a dividend, here is what the dividend and yield would be based on its trailing 12 month EPS multiplied by a range of hypothetical payout ratios: EPS (TTM)Payout RatioAnnual DividendYield 0.21 10% 0.0215 0.44% 0.21 20% 0.043 0.89% 0.21 30% 0.0645 1.33% 0.21 40%...